Recent submissions

  • Transcriptome-wide association study identifies new candidate susceptibility genes for glioma. 

    Atkins, I; Kinnersley, B; Ostrom, QT; Labreche, K; Il'yasova, D; Armstrong, GN; Eckel-Passow, JE; Schoemaker, MJ; Nöthen, MM; Barnholtz-Sloan, JS; Swerdlow, AJ; Simon, M; Rajaraman, P; Chanock, SJ; Shildkraut, J; Bernstein, JL; Hoffmann, P; Jöckel, K-H; Lai, RK; Claus, EB; Olson, SH; Johansen, C; Wrensch, MR; Melin, B; Jenkins, RB; Sanson, M; Bondy, ML; Houlston, RS (2019-02-01)
    Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of these GWAS susceptibility ...
  • Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. 

    Buus, R; Yeo, B; Brentnall, AR; Klintman, M; Cheang, MCU; Khabra, K; Sestak, I; Gao, Q; Cuzick, J; Dowsett, M (2018-09-04)
    BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...
  • Shared heritability and functional enrichment across six solid cancers. 

    Jiang, X; Finucane, HK; Schumacher, FR; Schmit, SL; Tyrer, JP; Han, Y; Michailidou, K; Lesseur, C; Kuchenbaecker, KB; Dennis, J; Conti, DV; Casey, G; Gaudet, MM; Huyghe, JR; Albanes, D; Aldrich, MC; Andrew, AS; Andrulis, IL; Anton-Culver, H; Antoniou, AC; Antonenkova, NN; Arnold, SM; Aronson, KJ; Arun, BK; Bandera, EV; Barkardottir, RB; Barnes, DR; Batra, J; Beckmann, MW; Benitez, J; Benlloch, S; Berchuck, A; Berndt, SI; Bickeböller, H; Bien, SA; Blomqvist, C; Boccia, S; Bogdanova, NV; Bojesen, SE; Bolla, MK; Brauch, H; Brenner, H; Brenton, JD; Brook, MN; Brunet, J; Brunnström, H; Buchanan, DD; Burwinkel, B; Butzow, R; Cadoni, G; Caldés, T; Caligo, MA; Campbell, I; Campbell, PT; Cancel-Tassin, G; Cannon-Albright, L; Campa, D; Caporaso, N; Carvalho, AL; Chan, AT; Chang-Claude, J; Chanock, SJ; Chen, C; Christiani, DC; Claes, KBM; Claessens, F; Clements, J; Collée, JM; Correa, MC; Couch, FJ; Cox, A; Cunningham, JM; Cybulski, C; Czene, K; Daly, MB; deFazio, A; Devilee, P; Diez, O; Gago-Dominguez, M; Donovan, JL; Dörk, T; Duell, EJ; Dunning, AM; Dwek, M; Eccles, DM; Edlund, CK; Edwards, DRV; Ellberg, C; Evans, DG; Fasching, PA; Ferris, RL; Liloglou, T; Figueiredo, JC; Fletcher, O; Fortner, RT; Fostira, F; Franceschi, S; Friedman, E; Gallinger, SJ; Ganz, PA; Garber, J; García-Sáenz, JA; Gayther, SA; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; Goode, EL; Goodman, MT; Goodman, G; Grankvist, K; Greene, MH; Gronberg, H; Gronwald, J; Guénel, P; Håkansson, N; Hall, P; Hamann, U; Hamdy, FC; Hamilton, RJ; Hampe, J; Haugen, A; Heitz, F; Herrero, R; Hillemanns, P; Hoffmeister, M; Høgdall, E; Hong, Y-C; Hopper, JL; Houlston, R; Hulick, PJ; Hunter, DJ; Huntsman, DG; Idos, G; Imyanitov, EN; Ingles, SA; Isaacs, C; Jakubowska, A; James, P; Jenkins, MA; Johansson, M; Johansson, M; John, EM; Joshi, AD; Kaneva, R; Karlan, BY; Kelemen, LE; Kühl, T; Khaw, K-T; Khusnutdinova, E; Kibel, AS; Kiemeney, LA; Kim, J; Kjaer, SK; Knight, JA; Kogevinas, M; Kote-Jarai, Z; Koutros, S; Kristensen, VN; Kupryjanczyk, J; Lacko, M; Lam, S; Lambrechts, D; Landi, MT; Lazarus, P; Le, ND; Lee, E; Lejbkowicz, F; Lenz, H-J; Leslie, G; Lessel, D; Lester, J; Levine, DA; Li, L; Li, CI; Lindblom, A; Lindor, NM; Liu, G; Loupakis, F; Lubiński, J; Maehle, L; Maier, C; Mannermaa, A; Marchand, LL; Margolin, S; May, T; McGuffog, L; Meindl, A; Middha, P; Miller, A; Milne, RL; MacInnis, RJ; Modugno, F; Montagna, M; Moreno, V; Moysich, KB; Mucci, L; Muir, K; Mulligan, AM; Nathanson, KL; Neal, DE; Ness, AR; Neuhausen, SL; Nevanlinna, H; Newcomb, PA; Newcomb, LF; Nielsen, FC; Nikitina-Zake, L; Nordestgaard, BG; Nussbaum, RL; Offit, K; Olah, E; Olama, AAA; Olopade, OI; Olshan, AF; Olsson, H; Osorio, A; Pandha, H; Park, JY; Pashayan, N; Parsons, MT; Pejovic, T; Penney, KL; Peters, WHM; Phelan, CM; Phipps, AI; Plaseska-Karanfilska, D; Pring, M; Prokofyeva, D; Radice, P; Stefansson, K; Ramus, SJ; Raskin, L; Rennert, G; Rennert, HS; van Rensburg, EJ; Riggan, MJ; Risch, HA; Risch, A; Roobol, MJ; Rosenstein, BS; Rossing, MA; De Ruyck, K; Saloustros, E; Sandler, DP; Sawyer, EJ; Schabath, MB; Schleutker, J; Schmidt, MK; Setiawan, VW; Shen, H; Siegel, EM; Sieh, W; Singer, CF; Slattery, ML; Sorensen, KD; Southey, MC; Spurdle, AB; Stanford, JL; Stevens, VL; Stintzing, S; Stone, J; Sundfeldt, K; Sutphen, R; Swerdlow, AJ; Tajara, EH; Tangen, CM; Tardon, A; Taylor, JA; Teare, MD; Teixeira, MR; Terry, MB; Terry, KL; Thibodeau, SN; Thomassen, M; Bjørge, L; Tischkowitz, M; Toland, AE; Torres, D; Townsend, PA; Travis, RC; Tung, N; Tworoger, SS; Ulrich, CM; Usmani, N; Vachon, CM; Van Nieuwenhuysen, E; Vega, A; Aguado-Barrera, ME; Wang, Q; Webb, PM; Weinberg, CR; Weinstein, S; Weissler, MC; Weitzel, JN; West, CML; White, E; Whittemore, AS; Wichmann, H-E; Wiklund, F; Winqvist, R; Wolk, A; Woll, P; Woods, M; Wu, AH; Wu, X; Yannoukakos, D; Zheng, W; Zienolddiny, S; Ziogas, A; Zorn, KK; Lane, JM; Saxena, R; Thomas, D; Hung, RJ; Diergaarde, B; McKay, J; Peters, U; Hsu, L; García-Closas, M; Eeles, RA; Chenevix-Trench, G; Brennan, PJ; Haiman, CA; Simard, J; Easton, DF; Gruber, SB; Pharoah, PDP; Price, AL; Pasaniuc, B; Amos, CI; Kraft, P; Lindström, S (2019-01-25)
    Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total ...
  • SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. 

    Carreno, G; Boult, JKR; Apps, JR; Gonzalez-Meljem, JM; Haston, S; Guiho, R; Stache, C; Danielson, LS; Koers, A; Smith, LS; Virasami, A; Panousopoulos, L; Buchfelder, M; Jacques, TS; Chesler, L; Robinson, S; Martinez-Barbera, JP (2019-01-01)
    Pharmacological inhibition of the sonic hedgehog (SHH) pathway can be beneficial against certain cancers but detrimental in others. Adamantinomatous craniopharyngioma (ACP) is a relevant pituitary tumour, affecting children ...
  • Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

    Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS (2019-01-10)
    The original version of this Article contained an error in the spelling of a member of the PRACTICAL Consortium, Manuela Gago-Dominguez, which was incorrectly given as Manuela Gago Dominguez. This has now been corrected ...
  • Mendelian randomization provides support for obesity as a risk factor for meningioma. 

    Takahashi, H; Cornish, AJ; Sud, A; Law, PJ; Disney-Hogg, L; Calvocoressi, L; Lu, L; Hansen, HM; Smirnov, I; Walsh, KM; Schramm, J; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Schildkraut, JM; Simon, M; Bondy, M; Wrensch, M; Wiemels, JL; Claus, EB; Turnbull, C; Houlston, RS (2019-01-22)
    Little is known about the causes of meningioma. Obesity and obesity-related traits have been reported in several epidemiological observational studies to be risk factors for meningioma. We performed an analysis of genetic ...
  • Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. 

    Oser, MG; Fonseca, R; Chakraborty, AA; Brough, R; Spektor, A; Jennings, RB; Flaifel, A; Novak, JS; Gulati, A; Buss, E; Younger, ST; McBrayer, SK; Cowley, GS; Bonal, DM; Nguyen, Q-D; Brulle-Soumare, L; Taylor, P; Cairo, S; Ryan, CJ; Pease, EJ; Maratea, K; Travers, J; Root, DE; Signoretti, S; Pellman, D; Ashton, S; Lord, CJ; Barry, ST; Kaelin, WG (2018-10-29)
    Small cell lung cancer (SCLC) accounts for 15% of lung cancers and is almost always linked to inactivating RB1 and TP53 mutations. SCLC frequently responds, albeit briefly, to chemotherapy. The canonical function of the ...
  • Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C. 

    Cornish, AJ; Hoang, PH; Dobbins, SE; Law, PJ; Chubb, D; Orlando, G; Houlston, RS (2019-01-08)
    The identification of driver mutations is fundamental to understanding oncogenesis. Although genes frequently mutated in B-cell lymphoma have been identified, the search for driver mutations has largely focused on the ...
  • Publisher Correction: Cancer genetics, precision prevention and a call to action. 

    Turnbull, C; Sud, A; Houlston, RS (2019-01)
    In the version of this article originally published, there was an error in the second-to-last sentence of the abstract. In this sentence, the final phrase "to identify carriers of first-wave gene mutation carriers" should ...
  • Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. 

    Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; Law, PJ; Johnson, DC; Mirabella, F; Holroyd, A; Li, N; Orlando, G; Weinhold, N; van Duin, M; Chen, B; Mitchell, JS; Mansouri, L; Juliusson, G; Smedby, KE; Jayne, S; Majid, A; Dearden, C; Allsup, DJ; Bailey, JR; Pratt, G; Pepper, C; Fegan, C; Rosenquist, R; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Einsele, H; Gregory, WM; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Hansson, M; Goldschmidt, H; Dyer, MJS; Kaiser, M; Sonneveld, P; Morgan, GJ; Hemminki, K; Nilsson, B; Catovsky, D; Allan, JM; Houlston, RS (2018-12-21)
    The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ...
  • Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. 

    Moreno, L; Casanova, M; Chisholm, JC; Berlanga, P; Chastagner, PB; Baruchel, S; Amoroso, L; Gallego Melcón, S; Gerber, NU; Bisogno, G; Fagioli, F; Geoerger, B; Glade Bender, JL; Aerts, I; Bergeron, C; Hingorani, P; Elias, I; Simcock, M; Ferrara, S; Le Bruchec, Y; Slepetis, R; Chen, N; Vassal, G (2018-09)
    BACKGROUND: nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with ...
  • Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. 

    Johnston, S; Puhalla, S; Wheatley, D; Ring, A; Barry, P; Holcombe, C; Boileau, JF; Provencher, L; Robidoux, A; Rimawi, M; McIntosh, SA; Shalaby, I; Stein, RC; Thirlwell, M; Dolling, D; Morden, J; Snowdon, C; Perry, S; Cornman, C; Batten, LM; Jeffs, LK; Dodson, A; Martins, V; Modi, A; Osborne, CK; Pogue-Geile, KL; Cheang, MCU; Wolmark, N; Julian, TB; Fisher, K; MacKenzie, M; Wilcox, M; Huang Bartlett, C; Koehler, M; Dowsett, M; Bliss, JM; Jacobs, SA (2019-01-20)
    PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination ...
  • A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. 

    Menon, M; Elliott, R; Bowers, L; Balan, N; Rafiq, R; Costa-Cabral, S; Munkonge, F; Trinidade, I; Porter, R; Campbell, AD; Johnson, ER; Esdar, C; Buchstaller, H-P; Leuthner, B; Rohdich, F; Schneider, R; Sansom, O; Wienke, D; Ashworth, A; Lord, CJ (2019-01-17)
    Inhibition of the PARP superfamily tankyrase enzymes suppresses Wnt/β-catenin signalling in tumour cells. Here, we describe here a novel, drug-like small molecule inhibitor of tankyrase MSC2504877 that inhibits the growth ...
  • Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts 

    Calvo, F; Ferrari, N; Ranftl, R; Chicherova, I; Slaven, ND; Moeendarbary, E; Farrugia, AJ; Lam, M; Semiannikova, M; Westergaard, MCW; Tchou, J; Magnani, L
    Aggressive behaviours of solid tumours are influenced by the tumour microenvironment. Multiple signalling pathways can influence the behaviour of stromal fibroblasts in tumours, but how these events are coordinated to ...
  • Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. 

    Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; Hockaday, A; Jones, JR; Kishore, B; Garg, M; Williams, CD; Karunanithi, K; Lindsay, J; Jenner, MW; Cook, G; Russell, NH; Kaiser, MF; Drayson, MT; Owen, RG; Gregory, WM; Morgan, GJ; UK NCRI Haemato-oncology Clinical Studies Group (2019-01)
    BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ...
  • The genomic landscape of plasma cells in systemic light chain amyloidosis. 

    Boyle, EM; Ashby, C; Wardell, CP; Rowczenio, D; Sachchithanantham, S; Wang, Y; Johnson, SK; Bauer, MA; Weinhold, N; Kaiser, MF; Johnson, DC; Jones, JR; Pawlyn, C; Proszek, P; Schinke, C; Facon, T; Dumontet, C; Davies, FE; Morgan, GJ; Walker, BA; Wechalekar, AD (2018-12-27)
  • Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

    Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)
    Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
  • MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. 

    Ghidini, M; Hahne, JC; Frizziero, M; Tomasello, G; Trevisani, F; Lampis, A; Passalacqua, R; Valeri, N (2018-08)
    Receptor tyrosine kinases (RTKs) are widely expressed transmembrane proteins that act as receptors for growth factors and other extracellular signalling molecules. Upon ligand binding, RTKs activate intracellular signalling ...
  • Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. 

    Bisogno, G; Jenney, M; Bergeron, C; Gallego Melcón, S; Ferrari, A; Oberlin, O; Carli, M; Stevens, M; Kelsey, A; De Paoli, A; Gaze, MN; Martelli, H; Devalck, C; Merks, JH; Ben-Arush, M; Glosli, H; Chisholm, J; Orbach, D; Minard-Colin, V; De Salvo, GL; European paediatric Soft tissue sarcoma Study Group (2018-08)
    BACKGROUND: Rhabdomyosarcoma is an aggressive tumour that can develop in almost any part of the body. Doxorubicin is an effective drug against rhabdomyosarcoma, but its role in combination with an established multidrug ...

View more